DNA methylation biomarkers with diagnostic, prognostic, and predictive power significantly linked to BC or epigenetic therapies of BC focusing on the therapeutic effects of DNA methyltransferase (DNMT) inhibitors are in ongoing clinical trials [73, 83, 206–214]. This evidence concerns the gene DNMT1 and breast cancer.